The Technical AnalystExchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Santhera Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.70% CHF9.26
America/New_York / 30 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 81.24 mill |
| EPS: | -8.63 |
| P/E: | -1.070 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 8.77 mill |
| Avg Daily Volume: | 0.0253 mill |
| RATING 2024-04-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.070 | sector: PE 25.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -1.070 | industry: PE 17.08 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CHF-0.459 (-104.96%) CHF-9.72 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
CHF 8.90 - 9.62 ( +/- 3.87%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CHF9.26 (-1.70% ) |
| Volume | 0.0147 mill |
| Avg. Vol. | 0.0253 mill |
| % of Avg. Vol | 58.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SANN.SW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SANN.SW
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.